
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Pharmaceutical science & technology news.
over 23 years ago
Drug Safety in the Limelightover 23 years ago
Outsourcing Outlookover 23 years ago
The Square Root of N Plus One Sampling Ruleover 23 years ago
Particle Attrition by Particle?Surface Friction in Dryers




